急性缺血性卒中血管内治疗后血压管理:BEST-II随机临床试验
BEST-II是一项2期无希望临床试验,纳入120例成功血管内治疗的急性缺血性卒中患者,随机分为收缩压目标<140 mmHg、<160 mmHg和≤180 mmHg(指南推荐)三组,再通后60分钟内启动并维持24小时。主要无希望分析显示,随访梗死体积斜率-0.29(95%CI -0.81至∞;无希望P=0.99),效用加权mRS斜率-0.0019(95%CI -∞至0.0017;无希望P=0.93),均未达到预设无希望界值。与高目标组相比,未来试验预测成功概率<140 mmHg组为25%,<160 mmHg组为14%。结论提示较低收缩压目标未达到无希望标准,但未来大型试验获益概率低。
要点
- 急性缺血性卒中成功血管内治疗后,收缩压目标<140 mmHg或<160 mmHg与≤180 mmHg相比,未达到预设无希望标准(梗死体积斜率无希望P=0.99,效用加权mRS斜率无希望P=0.93)。
- 随访梗死体积均值:<140 mmHg组32.4 mL(95%CI 18.0-46.7),<160 mmHg组50.7 mL(95%CI 33.7-67.7),≤180 mmHg组46.4 mL(95%CI 24.5-68.2)。
- 效用加权mRS均值:<140 mmHg组0.51(95%CI 0.38-0.63),<160 mmHg组0.47(95%CI 0.35-0.60),≤180 mmHg组0.58(95%CI 0.46-0.71)。
- 与高目标组相比,未来两组优效性试验预测成功概率:<140 mmHg组25%,<160 mmHg组14%。
- 作者认为,较低收缩压目标未达到无希望标准,但若未来大型试验测试,获益概率低。
适用人群与场景
- 纳入:急性缺血性卒中并成功接受血管内治疗的患者,来自美国3个综合卒中中心,2020年1月至2022年3月入组,最终随访2022年6月。
诊断标准与关键阈值
- 无希望界值:随访梗死体积每20 mmHg收缩压目标降低增加10 mL(斜率0.5)或效用加权mRS每20 mmHg降低0.10(斜率-0.005),单侧α=0.05。
- 额外无希望标准:未来两组优效性试验预测成功概率<25%。
处置流程与药物剂量
- 血管内治疗后随机分配至收缩压目标<140 mmHg、<160 mmHg或≤180 mmHg(指南推荐)组,再通后60分钟内启动并维持24小时。
研究设计与关键结果
- 研究类型:随机、开放标签、盲法终点、2期无希望临床试验;样本量120例,3个美国综合卒中中心;平均年龄69.6岁(SD14.5),女性69例(58%);113例(94.2%)完成试验。
- 主要终点:随访梗死体积斜率-0.29(95%CI -0.81至∞;无希望P=0.99);效用加权mRS斜率-0.0019(95%CI -∞至0.0017;无希望P=0.93)。
- 随访梗死体积均值:<140 mmHg组32.4 mL(95%CI 18.0-46.7),<160 mmHg组50.7 mL(95%CI 33.7-67.7),≤180 mmHg组46.4 mL(95%CI 24.5-68.2)。
- 效用加权mRS均值:<140 mmHg组0.51(95%CI 0.38-0.63),<160 mmHg组0.47(95%CI 0.35-0.60),≤180 mmHg组0.58(95%CI 0.46-0.71)。
- 与高目标组相比,未来试验预测成功概率:<140 mmHg组25%,<160 mmHg组14%。
证据类型、等级与局限
- 证据类型:随机、开放标签、盲法终点、2期无希望临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,较低收缩压目标未达到无希望标准,但若未来大型试验测试,获益概率低。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The effects of moderate systolic blood pressure (SBP) lowering after successful recanalization with endovascular therapy for acute ischemic stroke are uncertain.
OBJECTIVE: To determine the futility of lower SBP targets after endovascular therapy (<140 mm Hg or 160 mm Hg) compared with a higher target (≤180 mm Hg).
DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, blinded end point, phase 2, futility clinical trial that enrolled 120 patients with acute ischemic stroke who had undergone successful endovascular therapy at 3 US comprehensive stroke centers from January 2020 to March 2022 (final follow-up, June 2022).
INTERVENTION: After undergoing endovascular therapy, participants were randomized to 1 of 3 SBP targets: 40 to less than 140 mm Hg, 40 to less than 160 mm Hg, and 40 to 180 mm Hg or less (guideline recommended) group, initiated within 60 minutes of recanalization and maintained for 24 hours.
MAIN OUTCOMES AND MEASURES: Prespecified multiple primary outcomes for the primary futility analysis were follow-up infarct volume measured at 36 (±12) hours and utility-weighted modified Rankin Scale (mRS) score (range, 0 [worst] to 1 [best]) at 90 (±14) days. Linear regression models were used to test the harm-futility boundaries of a 10-mL increase (slope of 0.5) in the follow-up infarct volume or a 0.10 decrease (slope of -0.005) in the utility-weighted mRS score with each 20-mm Hg SBP target reduction after endovascular therapy (1-sided α = .05). Additional prespecified futility criterion was a less than 25% predicted probability of success for a future 2-group, superiority trial comparing SBP targets of the low- and mid-thresholds with the high-threshold (maximum sample size, 1500 with respect to the utility-weighted mRS score outcome).
RESULTS: Among 120 patients randomized (mean [SD] age, 69.6 [14.5] years; 69 females [58%]), 113 (94.2%) completed the trial. The mean follow-up infarct volume was 32.4 mL (95% CI, 18.0 to 46.7 mL) for the less than 140-mm Hg group, 50.7 mL (95% CI, 33.7 to 67.7 mL), for the less than 160-mm Hg group, and 46.4 mL (95% CI, 24.5 to 68.2 mL) for the 180-mm Hg or less group. The mean utility-weighted mRS score was 0.51 (95% CI, 0.38 to 0.63) for the less than 140-mm Hg group, 0.47 (95% CI, 0.35 to 0.60) for the less than 160-mm Hg group, and 0.58 (95% CI, 0.46 to 0.71) for the high-target group. The slope of the follow-up infarct volume for each mm Hg decrease in the SBP target, adjusted for the baseline Alberta Stroke Program Early CT score, was -0.29 (95% CI, -0.81 to ∞; futility P = .99). The slope of the utility-weighted mRS score for each mm Hg decrease in the SBP target after endovascular therapy, adjusted for baseline utility-weighted mRS score, was -0.0019 (95% CI, -∞ to 0.0017; futility P = .93). Comparing the high-target SBP group with the lower-target groups, the predicted probability of success for a future trial was 25% for the less than 140-mm Hg group and 14% for the 160-mm Hg group.
CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke, lower SBP targets less than either 140 mm Hg or 160 mm Hg after successful endovascular therapy did not meet prespecified criteria for futility compared with an SBP target of 180 mm Hg or less. However, the findings suggested a low probability of benefit from lower SBP targets after endovascular therapy if tested in a future larger trial.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04116112.
参考来源
- Mistry EA, Hart KW, Davis LT, et al. Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial. JAMA. 2023. PMID: 37668620. doi:10.1001/jama.2023.14330
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。